2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P2750
    Cathepsin D 9025-26-7
    Cathepsin D (CTSD) is a lysosomal aspartic protease encoded by the CTSD gene. Cathepsin D regulates lysosomal protease activity. Loss of Cathepsin D leads to lysosomal dysfunction and the accumulation of various cellular proteins associated with neurodegenerative diseases. Cathepsin D is involved in breast cancer metastasis. Cathepsin D can be used in research on diseases such as breast cancer and stroke.
    Cathepsin D
  • HY-P2759
    Thioredoxin reductase 9074-14-0
    Thioredoxin reductase (TrxR) is a selenoprotein that plays a central role in cellular redox homeostasis by utilizing highly reactive selenocysteine ​​(Sec) residues exposed to solvents at its active site. Thioredoxin reductase can be used for the study of diverse diseases, from rheumatoid arthritis and ischemia to cancer and parasitic infections.
    Thioredoxin reductase
  • HY-P3138
    (Sar1)-Angiotensin II 51833-69-3 99.84%
    (Sar1)-Angiotensin II, an analogue of Angiotensin II, is a specific agonist of angiotensin AT1 receptor. (Sar1)-Angiotensin II binds to brain membrane-rich particles, with a Kd of 2.7 nM. (Sar1)-Angiotensin II can stimulate protein synthesis and cell growth in embryonic chick myocytes.
    (Sar1)-Angiotensin II
  • HY-P3557
    Mibenratide 1239011-83-6 99.47%
    Mibenratide, a small cyclic peptide, is an adrenergic β1 receptor antagonist. Mibenratide can be used for heart failure research.
    Mibenratide
  • HY-P3678
    Neuropeptide Y (18-36) (porcine) 114495-97-5 98.76%
    Neuropeptide Y (18-36) (porcine) is a competitive neuropeptide Y (NPY) cardiac receptor antagonist. Neuropeptide Y (18-36) (porcine) inhibits the binding of I-NPY to cardiac ventricular membranes in a concentration-dependent manner with an IC50 value of 158 nM and an Ki value of 140 nM. Neuropeptide Y (18-36) (porcine) can be used for the research of congestive heart failure.
    Neuropeptide Y (18-36) (porcine)
  • HY-P4420
    H-Lys-Trp-OH 50674-18-5 99.84%
    H-Lys-Trp-OH (KW) is an ACE inhibitory peptide with an IC50 of 7.8 μM.
    H-Lys-Trp-OH
  • HY-P4560
    H-Pro-Phe-OH 13589-02-1 99.14%
    H-Pro-Phe-OH is a dipeptide containing proline and phenylalanine, which can serve as a substrate for prolinase. H-Pro-Phe-OH can also be used for polypeptide synthesis, where phenylalanine is an aromatic amino acid that can inhibit the activity of Angiotensin-converting enzyme (ACE, HY-P2983).
    H-Pro-Phe-OH
  • HY-P4641
    H-Trp-Phe-OH 6686-02-8 99.87%
    H-Trp-Phe-OH (Trp-Phe) is an ACE inhibitor and endothelial function regulator, with an ACE IC50 of 0.318 mg/mL. H-Trp-Phe-OH increases nitric oxide concentration, reduces endothelin-1 (ET-1) levels, and reverses norepinephrine-mediated endothelial cell dysfunction. H-Trp-Phe-OH exhibits antihypertensive activity. H-Trp-Phe-OH can be used in studies related to hypertension and atherosclerosis.
    H-Trp-Phe-OH
  • HY-P4866
    Q-Peptide 1361235-89-3 99.46%
    Q-Peptide is an angiopoietin-1 derived peptide (QHREDGS). Q-Peptide interacts with β1-integrin, binds to integrins on the surface of osteoblasts, and serves as an acyl donor substrate for Streptomyces mobaraensis transglutaminase. Q-Peptide activates Akt, MAPKp42/44, ILK, ERK1/2, and downregulates caspase-3/7. Q-Peptide inhibits cell apoptosis, enhances cell adhesion and migration, and promotes osteoblast differentiation, bone matrix deposition and mineralization. Q-Peptide can be used in studies related to myocardial infarction, bone regeneration, diabetic wound repair and human induced pluripotent stem cells.
    Q-Peptide
  • HY-P6437
    Drp1 peptide inhibitor P110 2770267-63-3
    Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction.
    Drp1 peptide inhibitor P110
  • HY-Y0370
    6-Chlorooxindole 56341-37-8 99.25%
    6-Chlorooxindole (compound 2) is a selective chymase inhibitor with an IC50 of 470 μM. 6-Chlorooxindole shows >100-fold selectivity for chymase over cathepsin G. 6-Chlorooxindole can be used for the study of cardiovascular disease.
    6-Chlorooxindole
  • HY-Z0075
    (Z)2S,4R-Sacubitril
    (Z)2S,4R-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and agent Administration for use in combination with valsartan for the treatment of patients with heart failure.
    (Z)2S,4R-Sacubitril
  • HY-100418
    SKA-111 1369170-24-0 99.97%
    SKA-111 is a selective activator of potassium phannel KCa 3.1 , evokes KCa 3.1 membrane hyperpolarization in porcine endothelial cell. SKA-111 is capable of improving Bradykinin (HY-P0206)-induced coronary dilations in the isolated rat heart and can be used for cardiovascular disease research.
    SKA-111
  • HY-100952
    Nifenalol hydrochloride 5704-60-9 99.93%
    Nifenalol hydrochloride is a β-adrenergic receptor antagonist. Nifenalol hydrochloride induces the Early Afterdepolarization (EAD) effect. EAD is a phenomenon in cardiac electrophysiology that usually occurs during an action potential in ventricular muscle cells and can lead to arrhythmia. The EAD effect of Nifenalol hydrochloride can be blocked by Tetrodotoxin. Nifenalol hydrochloride is used in the study of conditions such as irregular heartbeat or high blood pressure.
    Nifenalol hydrochloride
  • HY-101245
    Pilsicainide hydrochloride 88069-49-2 99.94%
    Pilsicainide hydrochloride (SUN-1165) is an orally active sodium channel blocker and potent class Ic antiarrhythmic agent.
    Pilsicainide hydrochloride
  • HY-101390
    (+)-Niguldipine hydrochloride 113145-69-0 98.06%
    (+)-Niguldipine hydrochloride is a 1,4-DHP receptor ligand associated with L-type Ca2+ channels (with Ki values of 85 pmol/L in guinea pig skeletal muscle, 140 pmol/L in brain, and 45 pmol/L in heart) as well as an α1-adrenergic receptor ligand (with a Ki value of 78 nmol/L). (+)-Niguldipine hydrochloride shows much higher binding selectivity for α1α-adrenergic receptors than for α1B-adrenergic receptors. (+)-Niguldipine hydrochloride can be used in studies related to hypertension.
    (+)-Niguldipine hydrochloride
  • HY-101723
    Modecainide 81329-71-7 98.95%
    Modecainide is a major metabolite of Encainide, which is an antiarrhythmic agent.
    Modecainide
  • HY-103067
    A1899 498577-46-1 99.72%
    A1899 is a potent and highly selective blocker of the K2P channel TASK-1. A1899 has IC50 values of 35.1 nM and 7 nM for TASK-1 channels expressed in oocytes and CHO cells, respectively. A1899 is also an IKur blocker that can be used for the research of cardiovascular diseases.
    A1899
  • HY-103410
    Carmoxirole hydrochloride 115092-85-8 99.82%
    Carmoxirole hydrochloride (EMD 45609 hydrochloride) is a selective, peripherally acting dopamine D2 receptor agonist and exhibits antihypertensive activities in vivo.
    Carmoxirole hydrochloride
  • HY-105090
    Lerisetron 143257-98-1 99.69%
    Lerisetron is a potent 5-HT3 antagonists and possess high-affinity binding for the 5-HT3 receptors with pKi value of 9.2. Lerisetron has a potent ability to inhibit the 5-HT-evoked reflex bradycardia in urethane-anesthetized rats.
    Lerisetron
Cat. No. Product Name / Synonyms Application Reactivity